Log in or Sign up for Free to view tailored content for your specialty!
Fibromyalgia News
FDA clears laser therapy to treat fibromyalgia pain
The FDA has granted clearance to Multi Radiance Medical’s FibroLux therapy laser for the treatment of pain in patients with fibromyalgia, according to a company press release.
‘Paradigms of distrust’: Medical gaslighting leaves patients dismissed and disrespected
The word “gaslighting” has taken on a life of its own in recent years, being used in the context of interpersonal relationships, political discourse and online chatter alike.
Log in or Sign up for Free to view tailored content for your specialty!
Medical cannabis growing in acceptance, improves pain in several rheumatic diseases
ORLANDO — Medical cannabis is growing in acceptance and has benefits for managing pain in patients with rheumatic diseases, but more research is required, a presenter said at the 2022 Rheumatology Nurses Society Conference.
Myositis Awareness Month sheds light on patient voices, disease costs
Myositis Awareness Month is focused on raising awareness and amplifying voices for patients with diseases falling under the myositis umbrella.
FDA grants marketing approval for neuromodulation device to reduce fibromyalgia symptoms
The FDA has granted De Novo authorization for NeuroMetrix to market its Quell neuromodulation device as an aid for reducing fibromyalgia symptoms in adults with high pain sensitivity, according to a company press release.
More than 40% of patients with long COVID report ‘fibromyalgia-like’ multi-site pain
More than 40% of patients with long COVID experience “fibromyalgia-like,” multisite pain, according to data released by Tonix Pharmaceuticals.
COVID-19 has caused ‘significant negative impacts’ on patients with musculoskeletal pain
The COVID-19 pandemic has wrecked “significant negative impacts” on pain, function and treatment accessibility for individuals with chronic musculoskeletal pain, according to a speaker at the 2022 OARSI World Congress.
Cyclobenzaprine tablets fail phase 3 trial for fibromyalgia pain
A sublingual tablet form of the muscle relaxant cyclobenzaprine hydrochloride failed to achieve statistical significance in reducing fibromyalgia pain vs. placebo in a phase 3 trial, according to a press release.
Is fatigue the new frontier in rheumatology?
Fatigue is not a new problem to rheumatologists, as we recognize it as one of the most common and difficult patient complaints that confronts us.
'No clinically relevant effect': Duloxetine fails to impact chronic osteoarthritis pain
Adding duloxetine to usual care fails to result in any “clinically relevant effect” in patients with chronic hip or knee osteoarthritis pain, compared with usual care alone, according to data published in Arthritis & Rheumatology.
-
Headline News
Q&A: ‘We have to be worried’ about decline in measles vaccination
November 19, 20244 min read -
Headline News
Physicians encouraged to ‘embrace’ technology in practice management
November 19, 20245 min read -
Headline News
Artificial neural network has ‘excellent’ performance in predicting COPD exacerbations
November 20, 20242 min read
-
Headline News
Q&A: ‘We have to be worried’ about decline in measles vaccination
November 19, 20244 min read -
Headline News
Physicians encouraged to ‘embrace’ technology in practice management
November 19, 20245 min read -
Headline News
Artificial neural network has ‘excellent’ performance in predicting COPD exacerbations
November 20, 20242 min read